Full-year 2026 revenue guidance increased to $121 million -- $123 million.
U.K. Biobank selected NULISA to profile 80,000 samples for neurodegenerative markers.
Biopharmaceutical clients generated 49% of third-quarter revenue.
On its third-quarter 2026 earnings webcast call, held on Nov. 3, 2026, Alamar Biosciences (NASDAQ:ALMR) raised its full-year 2026 revenue guidance to between $121 million and $123 million. Consumables demand from biopharmaceutical customers is powering recurring revenue growth. Higher-margin kit sales are steadily improving profitability.
Three key takeaways from management's comments stand out.
Alamar Biosciences secured a selection for the U.K. Biobank Vanguard study, using NULISA, its protein detection platform, to profile 80,000 samples for neurodegenerative markers. Large population cohorts demonstrate that the technology reliably measures scarce protein signals at scale.
Running on NULISA in Nightingale's laboratories, the study will profile 220 neurologically relevant proteins across 80,000 blood samples from individuals who were healthy when they enrolled.
-- Yuling Luo, Chief Executive Officer
Biopharmaceutical clients generated 49% of third-quarter revenue, becoming the company's largest customer segment for the first time. Drug developers run long-term trials that require repeated purchases of testing kits, generating predictable recurring revenue.
Biopharma customers tend to run larger, more sustained studies that drive meaningful consumables pull-through over time, and we are encouraged by the growing traction of our platform in drug development.
-- Justin McAnear, Chief Financial Officer
The company plans to submit its ARGO HT/DX clinical instrument for Food and Drug Administration marketing authorization by late 2027. Entering clinical diagnostics opens population-scale screening opportunities beyond the academic research market.
To get there, we're in the process of developing ARGO HT/DX, our clinical instrument and plan to submit for FDA marketing authorization by the end of next year.
-- Yuling Luo, Chief Executive Officer
Instrument placements are expanding across research institutions, driving recurring sales of testing kits. High technical sensitivity and multi-marker capabilities create a distinct moat as leadership monitors study execution.
On goals one and 2, we remain on track to grow our installed base by at least 100 instruments in 2026 and to maintain per instrument pull-through above $400,000.
-- Yuling Luo, Chief Executive Officer
Broadening disease panel offerings creates a bridge from basic research into clinical diagnostics.
Looking to 2027, we plan to keep expanding our installed base, launch a multiplex panel in a new disease area, submit ARGO HT/DX for FDA marketing authorization and establish partnerships to support our diagnostic strategy.
-- Yuling Luo, Chief Executive Officer
Before you buy stock in Alamar Biosciences, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alamar Biosciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,325!*
Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 22, 2026.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.